AIA Group Ltd trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 2.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,608 shares of the company’s stock after selling 66 shares during the period. AIA Group Ltd’s holdings in IDEXX Laboratories were worth $850,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in IDEXX Laboratories by 82.5% during the second quarter. FMR LLC now owns 2,067,814 shares of the company’s stock valued at $725,243,000 after acquiring an additional 934,829 shares during the period. Brown Advisory Inc. boosted its holdings in IDEXX Laboratories by 1.4% during the second quarter. Brown Advisory Inc. now owns 1,122,517 shares of the company’s stock valued at $408,669,000 after purchasing an additional 15,886 shares in the last quarter. Capital World Investors boosted its holdings in IDEXX Laboratories by 0.5% during the first quarter. Capital World Investors now owns 999,102 shares of the company’s stock valued at $546,577,000 after purchasing an additional 4,587 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in IDEXX Laboratories by 13.3% during the second quarter. JPMorgan Chase & Co. now owns 432,862 shares of the company’s stock valued at $151,818,000 after purchasing an additional 50,869 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in IDEXX Laboratories by 1.8% during the second quarter. Goldman Sachs Group Inc. now owns 392,982 shares of the company’s stock valued at $137,831,000 after purchasing an additional 7,019 shares in the last quarter. 87.90% of the stock is currently owned by institutional investors.
Insider Activity at IDEXX Laboratories
In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 13,230 shares of the stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $382.49, for a total value of $5,060,342.70. Following the transaction, the chief executive officer now directly owns 62,307 shares of the company’s stock, valued at approximately $23,831,804.43. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP Kathy V. Turner sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $436.00, for a total transaction of $1,308,000.00. Following the transaction, the senior vice president now directly owns 6,923 shares of the company’s stock, valued at $3,018,428. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 13,230 shares of the firm’s stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $382.49, for a total transaction of $5,060,342.70. Following the transaction, the chief executive officer now directly owns 62,307 shares in the company, valued at $23,831,804.43. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,516 shares of company stock worth $12,541,681. Insiders own 2.06% of the company’s stock.
Analyst Ratings Changes
IDEXX Laboratories Price Performance
Shares of NASDAQ IDXX opened at $486.70 on Wednesday. The firm has a market cap of $40.31 billion, a PE ratio of 61.84, a PEG ratio of 3.04 and a beta of 1.18. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 1.60. IDEXX Laboratories, Inc. has a 1-year low of $317.06 and a 1-year high of $574.33. The company has a fifty day moving average price of $431.01 and a 200 day moving average price of $387.98.
IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last announced its earnings results on Tuesday, November 1st. The company reported $2.15 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.11. IDEXX Laboratories had a net margin of 20.05% and a return on equity of 118.38%. The firm had revenue of $841.66 million during the quarter, compared to analyst estimates of $829.23 million. Research analysts predict that IDEXX Laboratories, Inc. will post 7.89 earnings per share for the current fiscal year.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
See Also
- Get a free copy of the StockNews.com research report on IDEXX Laboratories (IDXX)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
